Tech Cell Innovations Private Limited

TCIPL, a young biotech startup is not only at the forefront of regenerative medicine but is also integrating cutting-edge nanotechnology and sustainable practices into its innovative healthcare solutions. Leveraging the incredible potential of stem cells, particularly exosomes derived from these cells, the company is pioneering cell-free therapeutic options for various Biomedical applications such as burns/ traumatic wounds. By harnessing the regenerative properties of exosomes, the startup aims to develop advanced, cell-free therapies that can be administered more effectively than traditional methods, potentially transforming the landscape of wound care. In a commendable move towards sustainability, the startup has adopted a waste-to-value approach where we are sourcing stem cells from medical waste. This not only addresses environmental concerns associated with medical waste but also aligns with a broader commitment to ethical and sustainable healthcare practices. By merging regenerative medicine with nanotechnology and adopting a waste-to-value model, our startup exemplifies a holistic and forward-thinking approach to healthcare innovation. Current Stage of Development TCIPL has successfully obtained a 5 million INR seed grant through the 19th Call of the BIRAC-BIG Scheme, accelerating the advancement of an off-the-shelf cell-free product. The meticulous characterization of the product formulation and concurrent preclinical testing has been both rigorous and captivating. The technology is currently in the patent process, and TCIPL is actively seeking collaborations for large-scale manufacturing and upcoming clinical trials.